NCT01584674已完成3 期
A Prospective Clinical Trial Evaluating the Efficacy of the KLOX Biophotonic System (KLOX KLGA0105-01 and KLOX THERA LAMP) On Moderate to Severe Acne
KLOX Technologies Inc.6 个研究点 分布在 1 个国家目标入组 98 人开始时间: 2012年3月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 98
- 试验地点
- 6
- 主要终点
- Proportion of patients achieving a total reduction of at least 2 grades in the Investigator's Global Assessment (IGA) scale
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of the KLOX Biophotonic System in patients with moderate to severe facial acne vulgaris using a split-face design (treated hemiface vs untreated hemiface).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female 16 - 30 years of age.
- •Fitzpatrick skin type I through IV.
- •Known medical history of active acne vulgaris for at least 6 months.
- •Moderate-to-severe facial acne, as defined by:
- •Moderate is defined as a patient with an IGA of 3 with 20 to 40 inflammatory lesions (papules and pustules) and no more than 1 nodule. Severe is defined as a patient with an IGA of 4 with a greater than 40 inflammatory lesions with the presence of no more than 2 nodules and/or inflammatory scaring type lesion. Also note that all patients should have a similar disease stage on both sides of their face.
- •The patient must have a clinical examination prior to treatment.
- •The patient must have signed the consent form.
- •The patient must be willing to return for follow-up visits.
- •Females of child bearing potential must have a negative pregnancy test result at baseline and both male and female patients must be willing to adhere to a birth control method.
排除标准
- •Active skin infection on the face. Patient must not have active, localized or systemic infection.
- •Facial aesthetic procedure, including laser therapy and injectables within the last 6 months.
- •Enrollment in another acne study or other dermatological study using light therapy including tanning beds within 120 days of enrollment. Patients must not take part or intend to take part in another study liable to interfere with this study whatever the region of the body considered for 30 days prior to the study start and 30 days following completion of the study.
- •History of head and/or neck irradiation.
- •Use of a hormonal contraception is prohibited unless the birth control has been stable for the past 3 months. Note that patient that are presently taking or have taken in past 30 days Cyproterone Acetate + Ethinyl Estradiol (Diane-35) are not eligible for this study.
- •Any facial dermatological conditions that could hinder or interfere with clinical assessments.
- •Immunosuppression and/or cortisone therapy in the past 4 months.
- •Bleeding diathesis.
- •Medications or supplements affecting coagulation.
- •Isotretinoin within the last 24 weeks.
- •Pregnant, breast-feeding or pregnancy planned during the trial.
- •History of facial nerve palsy or marked facial asymmetry.
- •History of neuromuscular disorder.
- •Prior facial surgery that alters subcutaneous tissues (e.g., rhytidectomy).
- •Use of non-acne topical medication that could interfere with study treatment.
- •Physical or psychiatric condition the investigator deems would preclude participation in the study. (e.g. Polycystic Ovary disease)
- •Unwillingness to refrain from excess sun exposure or tanning beds during the healing process -
结局指标
主要结局
Proportion of patients achieving a total reduction of at least 2 grades in the Investigator's Global Assessment (IGA) scale
时间窗: 12 weeks
次要结局
- Reduction in inflammatory lesions(6 and 12 weeks)
- Proportion of patients achieving a reduction of at least 1 grade in the Investigator's Global Assessment (IGA) scale(6 and 12 weeks)
- Proportion of patients achieving a reduction to grade 1 or 0 in the Investigator's Global Assessment (IGA) scale(6 and 12 weeks)
- Patient satisfaction questionnaire(6 and 12 weeks)
- Pain assessment using a visual analogue scale(12 weeks)
- Safety evaluations (treatment-emergent and treatment related adverse events)(12 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
不适用
Assessment of the Evolution of Wound Biomarkers in Venous Leg Ulcers Treated With KLOX Biophotonic SystemVenous Leg UlcerNCT03593369KLOX Technologies Inc.25
已完成
不适用
EmoLED Medical Device Treatment of Second and Third Stage Pressure UlcersPressure SorePressure Ulcers Stage IIIPressure Ulcers Stage IIPressure UlcerNCT05130814Emoled48
进行中（未招募）
不适用
Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™WrinklePigmented LesionsNCT04727099Candela Corporation50
已完成
不适用
GreenLight XPS Laser System Retrospective Chart ReviewBenign Prostatic HyperplasiaNCT02139969Boston Scientific Corporation956
招募中
不适用
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot UlcersDiabetic Foot UlcerNCT05758545Piomic Medical450